Singapore's S*BIO Moving JAK2 Inhibitor Into Phase II In Early 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
S*BIO's collaboration with Onyx for two JAK2 inhibitors was one of the biggest biotech deals in Asia; data on one compound presented at ASH.
You may also be interested in...
Celgene Pays $340 Million For Gloucester And Its New Drug
Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.
S*BIO Collaborates With Singapore Hospital To Explore JAK2 Inhibitor Pathway
PERTH, Australia - Singapore-based S*BIO signed a collaboration agreement with Tan Tock Seng Hospital in Singapore to evaluate therapeutic effects of its JAK2 inhibitor SB1518 on biological samples from patients with myeloproliferative neoplasms, S*BIO announced Dec. 19
Undeclared APIs In ED Supplements From China Prompt FDA Warning
SHANGHAI - The U.S. FDA warned consumers Dec. 28 about using erectile dysfunction dietary supplements produced in China because some products contained undeclared active pharmaceutical ingredients